Denosumab Biosimilars Market Estimations (2025 - 2035)
The denosumab biosimilars market covers biosimilars referencing Prolia (denosumab 60 mg) for osteoporosis and bone loss and Xgeva (denosumab 120 mg) for prevention of skeletal-related events in patients with bone metastases and giant cell tumour of bone, in prefilled syringes and vials, interchangeable and non-interchangeable, sold through retail, specialty and hospital channels.
📄Report ID:2518
|
📊Format: Databook
|
📅Published: 19 November 2026
|
⚡Delivery: Immediate